New pooled data from three Galderma studies of the Restylane portfolio will be presented, demonstrating that treatments with Restylane RefyneTM and Restylane DefyneTM not only enhance ...

L’Oréal just announced it acquired a 10% stake in Galderma, characterized as a “pure play dermatology leader” in injectibles with Botox-competitor Dysport, and Restylane filler brands.

Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025.

(BUSINESS WIRE )--Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® LyftTM or ContourTM in combination with Sculptra® in patients ...

Galderma Group AG operates as a dermatology ... Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast ZUG, Switzerland, January 14, 2025--Galderma ...

Galderma Group AG operates as a dermatology ... Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin ...

including Relfydess (RelabotulinumtoxinA), Sculptra and Restylane. Alongside its community partners, Galderma will also host three symposia, a Mast ZUG, Switzerland, December 13, 2024--Galderma ...